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Knowledge about treatment of skin and soft tissue infections in 
injecting drug users in countries with low prevalence of 
antibiotic resistance is limited. We investigated bacterial 
antibiotic resistance and treatment of skin and soft tissue 
infections in Norwegian drug users. 
 
Methods 
We performed a two year clinical cross-sectional observational 
study in a Norwegian hospital. Data was collected 
retrospectively from hospital records. We examined 
bacteriological findings and antibiotic resistance and evaluated 
compliance to treatment guidelines and appropriateness of 
empirical antibiotic therapy relative to results of cultures and 




135 injecting drug users were admitted with skin and soft tissue 
infection in the study period. Cultures were obtained from 103 
(77%) abscesses and eight (24%) erysipelas and cellulitis, with 
bacterial growth in 80 (78%) and five (63%) respectively. 
Streptococci and staphylococci were the most prevalent bacteria, 
but methicillin resistant Staphylococcus aureus was found in 
only one patient. Compliance to hospital antibiotic guidelines 
was 70%. 91% of patients in the compliant and 79% in the non-
compliant group were given effective empirical antibiotics 
(p=0,334). In the non-compliant group, significantly more 
patients received broad-spectrum empirical antibiotics 
(p<0,001). In 30 cases where adjustment of antibiotic therapy 
was possible according to susceptibility testing, this was 
performed in only 14 cases. 
 
Conclusions 
Bacteria and resistance patterns did not differ significantly from 
skin and soft tissue infections in the general population in 
Norway. Compliance to antibiotic guidelines led to significantly 
less use of broad-spectrum antibiotics and to good bacterial 
coverage. General guidelines for treatment should be applied to 
injecting drug users with skin and soft tissue infections. 
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Skin- and soft tissue infections (SSTIs) are prevalent in people 
who inject drugs (PWID) [1-5], and constitute a substantial 
burden to the public health system [1, 2, 5, 6].  
The bacteria causing SSTIs are introduced from the 
commensal skin and oral flora and from contaminated drugs and 
injection paraphernalia [3, 5, 7-9]. In PWID, the dominating 
etiology is staphylococci and streptococci [2, 3, 5, 10-15]. Some 
studies, mainly from urban USA, show a high incidence of 
infections caused by methicillin resistant Staphylococcus aureus 
(MRSA) [3, 7, 10, 14-19]. Northern European studies have not 
reproduced these findings, except in isolated outbreaks [2, 13, 
16, 20]. Mixed infections with gram-negative rods and/or 
anaerobes are commonly seen [2, 3, 5, 10-13, 15, 19]. Outbreaks 
of infections with Clostridium and Bacillus species have been 
described [3, 5, 8, 9, 21, 22]. 
Studies show regional variations in antibiotic resistance 
over time [3, 9, 16]. We have limited information about the 
special features of SSTIs in PWID in areas with low-prevalence 
of resistant bacteria, and no recent studies have investigated the 
microbiology in SSTI in PWID in Norway.  
Our hypothesis was that, assuming differences between 
PWID and the common population in the distribution of bacteria 
causing SSTIs, PWID would be at risk of receiving 
inappropriate antibiotics if treated according to the general 
guidelines. We aimed to investigate the following issues:   
(1) Which bacteria and resistance patterns are found in SSTIs in 
an unselected hospitalized PWID population? 
(2)  
(A) Is treatment in compliance with Norwegian 
guidelines? 
(B) Is empirical antibiotic therapy appropriate relative to 
results of bacteriological cultures and susceptibility 
testing, and do cases receiving treatment with and 
without compliance to guidelines differ in this regard? 
(C) Is antibiotic therapy adjusted according to culture 
results and susceptibility testing?  
 
	  
Material and methods 
 
Design 
The study was retrospective with an observational cross-
sectional design.  
 
Sample, setting and observation period 
Oslo University Hospital Aker is a 323-bed tertiary care hospital 
serving unselected patients from a catchment area of 180.000 
people. All patients admitted during 2009 and 2010 with the 
following primary or secondary ICD-10-diagnosis were 
identified: L02 Cutaneous abscess, furuncle and carbuncle, L03 
Cellulitis, L04 Acute lymphadenitis, L05 Pilonidal cyst, L08 
Other local infections of skin and subcutaneous tissue and A46 
Erysipelas. Data was collected retrospectively from hospital 
records. Patients with no record of injecting drug use during the 
last month were excluded as were patients admitted and 
discharged the same day. Each admission was considered 
separately, but two or more subsequent admissions with an 
interval up to 14 days, identical foci and compatible culture 
results, were defined as one single incident. 184 episodes of 
SSTI in 135 PWID were identified. Only the first episode of 
infection in each patient was included in the statistical analyses. 
There was no follow-up after discharge.  
 
Measures 
Demographic and clinical data, bacterial culture results, 
including dates for sampling and reporting, and antibiotic 
treatment, were registered. Antibiotics prescribed before culture 
results were available were recorded as empirical. 
 
SSTIs were categorized as either abscess or erysipelas/cellulitis. 
The data did not enable us to distinguish erysipelas from 
cellulitis. Identification of bacterial species was performed by 
Gram stain and Vitek 2. Disk diffusion, E-test and Vitek 2 were 
used for susceptibility testing and susceptibility tests were 
interpreted according to EUCAST [23]. Cultures were obtained 
on clinical indication, set by the doctor who treated the patient. 
Additional foci were identified in order to avoid biasing of the 
evaluation of antibiotic therapy. We defined sepsis as systemic 
inflammatory response syndrome (SIRS) or SIRS and 
bacteremia. We noted sepsis or bacteraemia only if it affected 
choice of antibiotics. Blood cultures were not obtained from all 
patients.  
  
Guidelines for SSTI therapy 
In Aker Hospital guidelines, which are in accordance with 
national guidelines, penicillin is the drug of choice for erysipelas 
and dicloxacillin or cloxacillin for cellulitis. In patients with 
allergy to penicillins, erythromycin, cefalotin/cefalexin or 
clindamycin are antibiotics of choice. The guidelines emphasize 
that therapy should be adjusted according to culture and 
susceptibility results. The guidelines give no antibiotic 
recommendations regarding abscesses, but consensus is 
established that simple incision and drainage is the standard 
treatment. If antibiotics are indicated, dicloxacillin or cloxacillin 
are preferred and metronidazole might be added if anaerobic 
pathogens are suspected.  
 
Evaluation of antibiotic treatment  
Appropriateness of antibiotic treatment was evaluated for 
episodes in which empiric antibiotics were prescribed and 
positive culture results were achieved. Episodes with additional 
foci other than SSTI were excluded. Treatment was regarded as 
non-appropriate if isolated bacteria were of intermediate 
susceptibility or resistant, if an antibiotic with a lower minimum 
inhibitory concentration (MIC) could have been prescribed, or if 
treatment had unnecessarily broad spectrum. In most cases, 
evaluation was non-controversial, but some cases required 
consideration as follows.  
Against streptococci, penicillin was the drug of choice. 
Clindamycin prescribed to non-allergic patients was regarded 
non-appropriate due to unnecessarily broad spectrum, unless 
clindamycin was started empirically and continued after testing 
reported clindamycin sensitive streptococci. These cases were 
analyzed regarding empirical therapy, but excluded from 
analysis of adjusted therapy, as this was too controversial to 
judge in retrospect. Dicloxacillin and cloxacillin were regarded 
non-appropriate against streptococci, due to a higher MIC than 
penicillin.    
Against staphylococci, dicloxacillin or cloxacillin was 
the drug of choice. Although controversial, we regarded 
clindamycin appropriate if the staphylococci were susceptible, 
in order to give a conservative estimate of the proportion of non-
appropriate treatment. Penicillin was regarded as appropriate if 
the staphylococci were susceptible.  
 In cases with single isolates of streptococci or 
staphylococci, a combination of dicloxacillin or cloxacillin and 
penicillin was regarded non-appropriate due to unnecessary 
combination therapy and thus broad spectrum. In infections with 
isolation of both streptococci and staphylococci, the 
combination was regarded as appropriate, as was penicillin 
monotherapy, if the isolates were susceptible.  
 In anaerobic infections, we regarded metronidazole 
or penicillin as single therapy as appropriate, if isolates were 
susceptible. Other culture results were considered individually.  
Adjustment of antibiotic therapy was considered possible 
when results of cultures and susceptibility testing indicated this 
was an option.  
 
Statistics 
Descriptive and univariate statistics were used. 95% confidence 
intervals were calculated using estimated standard error. For 
bivariate analysis of categorical variables we used chi-square-
test or Fisher´s exact test. P values < 0,05 were considered 
statistically significant. SPSS versions 22 and 25 were used.  
 
Ethics  
The study was approved by the Regional Ethics Committee of 
South-East Norway and the Data Protection Officer for 
Research at Aker Hospital. We were granted exception from 
requiring informed consent in order to minimize the risk of 
selection bias, because the study population of PWID are often 
difficult to reach and have high mortality subsequently to 






During the two year study period 135 PWID were admitted with 
SSTI. 72% were men, and the mean age was 41,2 years.	  They 
constituted 21% of in-patient days for all SSTIs and 31% of 
abscesses, and 0,5% of all patients admitted. Many patients had 
more than one infection focus, maximum four. In all there were 
170 SSTI foci, of which 133 (78%) were abscesses. 19 patients 
(14%) had additional foci, and 11 of these had bacteraemia or 
sepsis, of which eight had bacteremia verified by blood culture.  
 
Bacteria and resistance patterns  
Cultures were obtained from 103 (77%) abscesses, with 
bacterial growth in 80 (78% of those cultured). In patients with 
erysipelas and cellulitis, eight cultures (24%) were obtained and 
five (63% of those cultured) had bacterial growth. Staphylococci 
and streptococci were the most prevalent bacteria. MRSA was 
found in only one patient. Ten isolates of Gram-negative rods 
and ten anaerobes, one of those Clostridium perfringens, were 
found [Table I]. In 16 foci, there were mixed cultures, with a 
maximum of four bacterial strains.  
All streptococci and 15% of staphylococci were 
susceptible to penicillin, while 90% of streptococci and 90% (CI 
80-100%) of S. aureus were susceptible to clindamycin.  
 
Antibiotic therapy 
Antibiotics were prescribed to 91% of patients with abscesses 
and to 88% with erysipelas/cellulitis. 90% of abscess cases were 
treated surgically, 7% with surgery only.  
There was compliance to guidelines in 59 (70%) patients 
with abscesses and in 12 (71%) patients with 
erysipelas/cellulitis. Antibiotics prescribed in the compliant and 
the non-compliant group are shown in Figure I.  
Further evaluation of erysipelas/cellulitis cases was 
restricted by sparse data. Regarding abscesses [Table II], 
antibiotic therapy in compliance to guidelines was appropriate in 
11 (32%) cases, compared to two (13%) cases with non-
compliant therapy (p=0,293). In the compliant group there was 
resistance to given antibiotics in three (9%) cases and in the 
non-compliant group in three (21%). Hence, effective empirical 
antibiotics were given to 91% in the compliant group and 79% 
in the non-compliant group (p=0,334). Only 6% in the 
compliant group received broad spectrum empirical antibiotics 
in contrast to 87% in non-compliant cases (p<0,001). In the 
compliant group 53% received a second choice agent as 
empirical antibiotic compared to 13% in the non-compliant 
group (p=0,014). 
In 37 cases where adjustment of antibiotic therapy was 
possible, including six cases with resistance to initial therapy, 
adjustment was performed in only 14 cases (38%). In seven 
cases we identified practical obstacles such as discharge from 
hospital before culture results were reported. In none of the 






As expected, staphylococci and streptococci were the most 
frequently isolated species.  
	  
Resistance  
Bacteria and resistance patterns did not differ significantly from 
cases with SSTI in the general Norwegian population. In 
accordance with studies from Switzerland and Sweden, MRSA 
was rarely isolated [2, 24]. There was a higher prevalence of S. 
aureus resistant to clindamycin than the 2,3% reported from the 
total Norwegian population [25]. Our results may indicate a 
specific feature regarding clindamycin resistant bacteria in the 
PWID population in Oslo. Emergence of resistance to 
clindamycin and tetracyclines has been observed in some 
communities, and awareness of regional susceptibility patterns 
is thus necessary [26]. 
 
Antibiotic treatment  
When compliant to guidelines, empiric antibiotic treatment was 
more often in accordance with culture results, as unnecessarily 
broad spectrum treatment was significantly more often 
prescribed in the non-compliant group. A substantial number of 
patients in the compliant group received second choice agents, 
as they were prescribed dicloxacillin or cloxacillin against 
streptococcal infections. This is an acceptable effect of covering 
empirically for possible staphylococcal infections.  
Adjustment of antibiotic therapy was done in only half of 
the cases where it was possible, and in none of the cases with 
resistance to initial treatment. This might indicate an adequate 
effect of surgery alone, as all these patients were treated 
surgically. Other studies in hospitalized patients have shown 
that adequately drained abscesses have high healing rates, also 
when patients are treated with non-effective antibiotics [27-29]. 
Only 7% of abscesses in our study were treated with incision 
and drainage alone. This might suggest overtreatment of 
abscesses with antibiotics, but it may also indicate that SSTIs in 
PWID are more severe than in other patients or that the patients 
were hospitalized due to more serious infections.  
There was no support for our hypothesis that PWID would 
receive inappropriate therapy if treated according to general 
guidelines. On the contrary, compliance to antibiotic guidelines 
led to significantly less use of broad-spectrum antibiotics and to 
good empirical coverage of bacteria. Our study revealed that 
there is still room for improvement of antibiotic therapy in this 
group of patients.  
 
 
Implications for surveillance  
The data in this study dates back to 2009/2010. There is no more 
recent corresponding data from Norway. It is important to 
monitor trends in pathogens and antibiotic resistance in PWID 
with SSTIs and compare to the general population.  
As expected we found a low prevalence of MRSA, but 
further surveillance is needed, as outbreaks have been seen in 
other countries.     
 
Public health  
The PWID population in Oslo constitutes less than 1% of the 
total adult population. Nevertheless, one fifth of all inpatient 
days due to SSTIs and one third of those due to abscesses 
occurred among PWID. In this study none of the patients died, 
which may be due to comprehensive hospital treatment. Since 
these infections seldom are lethal, their importance may be 
underestimated [2]. A Norwegian study found an incidence of 
local bacterial infections of 8,5 hospital treatment contacts per 
100 patient-years among PWID [30]. This underlines the 
vulnerability of PWIDs to such infections and the magnitude of 
drug injecting as a public health problem.  
 
Strengths and limitations 
This study refers to hospitalized patients and we do not know to 
what extent the findings are representative of SSTIs among non-
hospitalized PWID. In comparison with PWID population 
statistics from the Norwegian Institute for Alcohol and Drug 
Research (SIRUS), the sample was representative of PWID in 
Oslo regarding gender and substances used, but had a higher 
mean age of 41,2 years compared to 32-38 years in SIRUS 
materials [31]. It is probable that SSTIs resulting in 
hospitalization are more severe than average SSTIs within the 
PWID population with a greater proportion of infections where 
antibiotic treatment is indicated. Relevant characteristics of 
bacteria and antibiotic resistance unique to the PWID population 
would therefore likely be recognized in this sample. The 
observation period was two years and included patients from 
both surgical and medical wards. Hence, our observations 
regarding bacteria and antibiotic resistance are most likely 
representative of PWIDs in Oslo 2009/2010.  
Our data is limited by retrospective collection from 
hospital records. Data was, furthermore, collected some time 
ago. We did not include a control group. With a control group, 
we could to a larger extent have been able to distinguish factors 
related to the patient population of PWID from other factors 
such as regional factors and demographic factors.  We did not 
investigate subgroups of PWID in terms of abused drug 
preference. We have no information about the patients after 
discharge from hospital.   
	  
Conclusion 
Bacteria and antibiotic resistance patterns did not differ 
significantly from SSTIs in the general population in Norway. 
Compliance to antibiotic guidelines led to significantly less use 
of broad-spectrum antibiotics and to good coverage of bacteria. 
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Table II: Evaluation of empiric antibiotic treatment relative to 
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Figure I: Antibiotics prescribed in 71 treatment episodes with 







112 isolated strains; 102 from abscesses, six from erysipelas/cellulitis, four from foci 
unclear whether abscess or erysipelas/cellulitis 
 









 Staphylococci 35 (34, 25-43) 5 (83, 52-100) 42 (38, 29-47) 
            Staphylococcus aureus, MSSA 35 3 40a  
            Staphylococcus aureus, MRSA 0 2b    2 
 Streptococci 44 (43, 33-53) 1 (17, 0-48) 46 (41, 32-50) 
            Streptococci, Milleri-group 25 0 25 
            Streptococci gr A, beta-hemolytic 15 1 16 
            Streptococci gr B, beta-hemolytic 1 0 1 
            Streptococci gr G, beta-hemolytic 1 0 2a 
            Streptococci, alpha-hemolytic 1 0 1  
            Streptococci, non-specified 1 0 1 
 Anaerobe bacteria 10 (10, 4-16) 0 10 (9, 4-14) 
            Prevotella divines 1 0 1 
            Clostridium perfringens 1 0 1 
            Bacterioides fragilis 1 0 1  
            Peptostreptococci 1 0 1 
            Anaerobe bacteria, non-specified 6 0 6 
 Gram negative rods 10 (10, 4-16) 0 11 (10,4-16) 
            Escherichia coli 4 0 4 
            Citrobacter species, non-specified 2 0 2 
            Enterobacteriaceae, non-specified 1 0 1 
            Pseudomonas aeruginosa 0 0 1a 
            Gram negative rods, non-specified 3 0 3 
 Other 3 (3, 0-6) 0 3 (3, 0-6) 
            Enterococcus faecalis 2 0 2 
            Gram positive rods, non-specified 1 0 1 
 
a Cultured from foci, where it was unclear whether there was abscess or erysipelas/cellulitis. 












Evaluation of empiric antibiotic treatment relative to culture results in cases where 




Appropriateness of treatment of 34 abscess cases with compliance and 15 without 
compliance to guidelines 
 
 
     Appropriatea  Non-appropriatea p-valueb 
 
    
Compliance   11 (32)  23 (66)b   
           p=0,293 
Non-compliance  2 (13)   13 (87)b   
 




Resistance to the prescribed antibiotics, comparing 33 abscess cases with compliance and 14 
without compliance to guidelines 
      
     Resistance  No resistance   p-valueb 
 
Compliancec   3 (9)    30 (91)   
           p=0,334 
Non-complianced  3 (21)   11 (79)  
 




Prescribing of broad-spectrum empirical antibiotics, comparing 34 abscess cases with 
compliance and 15 without compliance to guidelines 
 
 
     Yes   No  p-valueb 
 
Compliance   2 (6)   32 (94)  
           p=<0,001 
  Non-compliance  13 (87)  2 (13)   
 
  Total    15   34 
 
 
Use of a second choice agent as empirical antibiotic, comparing 34 abscess cases with 
compliance and 15 without compliance to guidelines 
 
Yes   No   p-valueb 
 
Compliance   18 (53)  16 (47) 
            p=0,014 
  Non-compliance  2 (13)   13 (87)  
 
Total    20   29 
 
 
a Treatment was regarded as non-appropriate if the isolated bacteria showed intermediate susceptibility or total 
resistance, if an antibiotic with a lower minimum inhibitory concentration (MIC) could have been prescribed, or 
if the treatment was unnecessarily broad spectrum. 
b Fisher´s exact test 
c In one treatment episode with compliance to guidelines, resistance could not be adequately assessed, but 
treatment was non-appropriate due to use of second choice agent 
d In one treatment episode without compliance to guidelines, resistance could not be adequately assessed, but 





































Isolated bacteria and initial antibiotic choice in six episodes with resistance to empirical 
antibiotic therapy 
 






Surgery Culture result Adjusted 
Abscess Yes Dicloxacillin 
 
 
Yes E. coli and 
anaerobes 
Noa 
Abscess Yes Dicloxacillin 
 
 
Yes E. coli No 
Abscess Yes Dicloxacillin 
 
 
Yes Citrobacter sp. No 
Abscess No Penicillin and 
metronidazol 
Yes S. aureus No 
Abscess No Clindamycin 
 
 
Yes S. milleri Noa 
Abscess No Penicillin and 
dicloxacillin 
 
Yes S. aureusb Noa 
 
a  Culture result after discharge from hospital 





























a In the compliance group one patient was prescribed a combination of dicloxacillin and metronidazol.  
In the non-compliance group 10 patients were prescribed combinations of dicloxacillin, penicillin, 
ampicillin, amoxicillin, ciprofloxacin, cefalexin, clindamycin, metronidazol or gentamycin.  
b One treatment episode with bacteremia that did not interfere with treatment 
c No treatment episodes with foci other than SSTI 
 
Figure I 
Antibiotics prescribed in 71 treatment episodes with compliance to guidelines and 30 
treatment episodes with non-compliance 
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